155 related articles for article (PubMed ID: 32589926)
61. Targeted delivery and triggered release of liposomal doxorubicin enhances cytotoxicity against human B lymphoma cells.
Ishida T; Kirchmeier MJ; Moase EH; Zalipsky S; Allen TM
Biochim Biophys Acta; 2001 Dec; 1515(2):144-58. PubMed ID: 11718670
[TBL] [Abstract][Full Text] [Related]
62. PEGylated hyperbranched polyphosphoester based nanocarriers for redox-responsive delivery of doxorubicin.
Chen C; Zheng P; Cao Z; Ma Y; Li J; Qian H; Tao W; Yang X
Biomater Sci; 2016 Mar; 4(3):412-7. PubMed ID: 26626655
[TBL] [Abstract][Full Text] [Related]
63. Development of biotin molecule targeted cancer cell drug delivery of doxorubicin loaded κ-carrageenan grafted graphene oxide nanocarrier.
Vinothini K; Rajendran NK; Munusamy MA; Alarfaj AA; Rajan M
Mater Sci Eng C Mater Biol Appl; 2019 Jul; 100():676-687. PubMed ID: 30948104
[TBL] [Abstract][Full Text] [Related]
64. Doxorubicin encapsulated in stealth liposomes conferred with light-triggered drug release.
Luo D; Carter KA; Razi A; Geng J; Shao S; Giraldo D; Sunar U; Ortega J; Lovell JF
Biomaterials; 2016 Jan; 75():193-202. PubMed ID: 26513413
[TBL] [Abstract][Full Text] [Related]
65. Lymphoma Immunochemotherapy: Targeted Delivery of Doxorubicin via a Dual Functional Nanocarrier.
Zhai Q; Chen Y; Xu J; Huang Y; Sun J; Liu Y; Zhang X; Li S; Tang S
Mol Pharm; 2017 Nov; 14(11):3888-3895. PubMed ID: 28850241
[TBL] [Abstract][Full Text] [Related]
66. Doxorubicin loaded liposomes for lung tumor targeting: in vivo cell line study in human lung cancer.
Guo Y; Zhu Q; Shi J; Li Y; Fu D; Qiao D; Chen S; Yang Y; Wang Y
J BUON; 2020; 25(3):1504-1511. PubMed ID: 32862597
[TBL] [Abstract][Full Text] [Related]
67. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737
[TBL] [Abstract][Full Text] [Related]
68. Reductively degradable α-amino acid-based poly(ester amide)-graft-galactose copolymers: facile synthesis, self-assembly, and hepatoma-targeting doxorubicin delivery.
Lv J; Sun H; Zou Y; Meng F; Dias AA; Hendriks M; Feijen J; Zhong Z
Biomater Sci; 2015 Jul; 3(7):1134-46. PubMed ID: 26221946
[TBL] [Abstract][Full Text] [Related]
69. Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy.
He Y; Su Z; Xue L; Xu H; Zhang C
J Control Release; 2016 May; 229():80-92. PubMed ID: 26945977
[TBL] [Abstract][Full Text] [Related]
70. Hyaluronidase Embedded in Nanocarrier PEG Shell for Enhanced Tumor Penetration and Highly Efficient Antitumor Efficacy.
Zhou H; Fan Z; Deng J; Lemons PK; Arhontoulis DC; Bowne WB; Cheng H
Nano Lett; 2016 May; 16(5):3268-77. PubMed ID: 27057591
[TBL] [Abstract][Full Text] [Related]
71. Synthesis of Cross-linked Poly (N-isopropylacrylamide) Magnetic Nano Composite for Application in the Controlled Release of Doxorubicin.
Kaamyabi S; Badrian A; Akbarzadeh A
Pharm Nanotechnol; 2017; 5(1):67-75. PubMed ID: 28948911
[TBL] [Abstract][Full Text] [Related]
72. In vivo distribution and antitumor activity of doxorubicin-loaded N-isopropylacrylamide-co-methacrylic acid coated mesoporous silica nanoparticles and safety evaluation.
Chen Y; Yang W; Chang B; Hu H; Fang X; Sha X
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):406-12. PubMed ID: 23816639
[TBL] [Abstract][Full Text] [Related]
73. Facile preparation of core cross-linked nanomicelles based on graft copolymers with pH responsivity and reduction sensitivity for doxorubicin delivery.
Chen T; Xiao Y; Lu W; Liu S; Gan L; Yu J; Huang J
Colloids Surf B Biointerfaces; 2018 Jan; 161():606-613. PubMed ID: 29156337
[TBL] [Abstract][Full Text] [Related]
74. Hierarchical self-assembly of heparin-PEG end-capped porous silica as a redox sensitive nanocarrier for doxorubicin delivery.
Nguyen Thi TT; Tran TV; Tran NQ; Nguyen CK; Nguyen DH
Mater Sci Eng C Mater Biol Appl; 2017 Jan; 70(Pt 2):947-954. PubMed ID: 27772725
[TBL] [Abstract][Full Text] [Related]
75. Mixed micelles for encapsulation of doxorubicin with enhanced in vitro cytotoxicity on breast and ovarian cancer cell lines versus Doxil
Cagel M; Bernabeu E; Gonzalez L; Lagomarsino E; Zubillaga M; Moretton MA; Chiappetta DA
Biomed Pharmacother; 2017 Nov; 95():894-903. PubMed ID: 28903185
[TBL] [Abstract][Full Text] [Related]
76. Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity.
Jung SH; Jung SH; Seong H; Cho SH; Jeong KS; Shin BC
Int J Pharm; 2009 Dec; 382(1-2):254-61. PubMed ID: 19666094
[TBL] [Abstract][Full Text] [Related]
77. Determination of key parameters for a mechanism-based model to predict Doxorubicin release from actively loaded liposomes.
Csuhai E; Kangarlou S; Xiang TX; Ponta A; Bummer P; Choi D; Anderson BD
J Pharm Sci; 2015 Mar; 104(3):1087-98. PubMed ID: 25561354
[TBL] [Abstract][Full Text] [Related]
78. A strategy for oral chemotherapy via dual pH-sensitive polyelectrolyte complex nanoparticles to achieve gastric survivability, intestinal permeability, hemodynamic stability and intracellular activity.
Deng L; Dong H; Dong A; Zhang J
Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):107-17. PubMed ID: 26515259
[TBL] [Abstract][Full Text] [Related]
79. Selenium-functionalized liposomes for systemic delivery of doxorubicin with enhanced pharmacokinetics and anticancer effect.
Xie Q; Deng W; Yuan X; Wang H; Ma Z; Wu B; Zhang X
Eur J Pharm Biopharm; 2018 Jan; 122():87-95. PubMed ID: 29032193
[TBL] [Abstract][Full Text] [Related]
80. Low Intensity Ultrasound Mediated Liposomal Doxorubicin Delivery Using Polymer Microbubbles.
Yu FT; Chen X; Wang J; Qin B; Villanueva FS
Mol Pharm; 2016 Jan; 13(1):55-64. PubMed ID: 26567985
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
